[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"radiodermatitis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:radiodermatitis":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,47],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":28,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":4},"100642414","artificial-intelligence-powered-digital-education-based-on-the-neuman-systems-model-for-breast-cancer-patients-receiving-radiotherap-100642414",false,"NCT07649902","Artificial Intelligence Powered Digital Education Based on the Neuman Systems Model for Breast Cancer Patients Receiving Radiotherap","The Effect of Artificial Intelligence-Powered Digital Education Based on the Neuman Systems Model on Radiodermatitis Severity and Quality of Life in Breast Cancer Patients","Inclusion Criteria:\n\n* Women aged 18 years or older diagnosed with primary breast cancer who have completed surgical treatment and are scheduled to receive adjuvant radiotherapy.\n* Patients who will receive radiotherapy for the first time.\n* Patients whose general health condition is suitable for participation in the study and follow-up assessments.\n* Patients who are able to read, understand, and communicate in Turkish.\n* Patients who have access to the internet and are able to use a smartphone, tablet, or computer to access the digital education program.\n* Patients who voluntarily agree to participate in the study and provide written informed consent.\n\nExclusion Criteria:\n\n* Previous radiotherapy to the same treatment area.\n* Presence of an active infection, open wound, or severe dermatological disease within the radiation treatment field.\n* History of a chronic skin condition that may affect radiation-induced skin reactions.\n* Cognitive or psychiatric conditions that may prevent participants from following the educational program or complying with the study procedures and data collection process.","FEMALE","18 Years",{"count":19,"type":20},38,"ESTIMATED","INTERVENTIONAL",[23],"NA","The purpose of this clinical trial is to evaluate the effect of an artificial intelligence-supported digital education program developed based on the Neuman Systems Model on radiodermatitis severity and quality of life in women with breast cancer receiving radiotherapy.\n\nThe intervention was developed based on the Neuman Systems Model, which served as the theoretical framework of the study. Educational content was structured according to the principles of the model and was designed to strengthen patients' flexible lines of defense, support resistance resources, facilitate adaptation to radiotherapy-related stressors, and promote system stability through primary, secondary, and tertiary prevention strategies.\n\nThe study aims to answer the following questions:\n\n* Is a Neuman Systems Model-based AI-supported digital education program effective in reducing the severity of radiotherapy-induced radiodermatitis?\n* Is a Neuman Systems Model-based AI-supported digital education program effective in improving quality of life among women receiving radiotherapy for breast cancer? Participants assigned to the intervention group will be provided with access to the AI-supported digital education program developed in accordance with the Neuman Systems Model, whereas participants assigned to the control group will receive standard care. Differences between the groups with respect to radiodermatitis severity and quality of life outcomes will be evaluated.\n\nParticipants will complete a Patient Information Form to collect sociodemographic and clinical characteristics prior to the initiation of radiotherapy. Radiodermatitis severity will be assessed using the Radiation Therapy Oncology Group (RTOG) Acute Radiation Dermatitis Scale, and quality of life will be evaluated using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) and the breast cancer-specific module (EORTC QLQ-BR23). Following these assessments, participants will be randomly allocated to either the intervention group or the control group. Radiodermatitis severity will be evaluated weekly throughout the radiotherapy period using the RTOG scale and reassessed two weeks after completion of radiotherapy. Quality of life will be evaluated before radiotherapy and reassessed two weeks after completion of radiotherapy using the EORTC QLQ-C30 and EORTC QLQ-BR23 questionnaires. Participants assigned to the intervention group will be provided with access to an AI-supported digital education platform incorporating educational modules, personalized educational recommendations, reminder notifications, and motivational messages. In addition, system usability will be evaluated at the end of the intervention period using the System Usability Scale (SUS).",[26,27],"Breast Cancer","Radiodermatitis",[26,29,27,30,31,32,33,34],"Radiotherapy","Quality of Life","Artificial Intelligence","Digital Education","Neuman Systems Model","Nursing Intervention","NOT_YET_RECRUITING","2026-06-11",{"date":38,"type":39},"2026-06-16","ACTUAL",{"date":41,"type":20},"2026-08-01",{"date":43,"type":20},"2027-07-01",{"name":45,"class":46},"Ataturk University","OTHER",{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":4,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":54,"minAge":17,"maxAge":55,"enrollmentInfo":56,"targetDuration":4,"studyType":21,"phases":58,"briefSummary":60,"conditions":61,"keywords":63,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":77,"locationsCount":79},"100595186","phase-2-taurines-therapeutic-effect-on-acute-radiation-induced-oral-mucositis-and-dermatitis-100595186","NCT07029178","Taurine's Therapeutic Effect on Acute Radiation-induced Oral Mucositis and Dermatitis","A Randomized Controlled Trial on Taurine's Therapeutic Effect on Acute Radiation-induced Oral Mucositis and Dermatitis","Inclusion Criteria:\n\n1. Patients voluntarily joined the study, were informed of the purpose and process of the study, signed the informed consent form, and were willing and able to abide by the study protocol.\n2. Aged 18 to 80, with no gender restrictions.\n3. Patients that require radiotherapy after surgery for oral\u002Foropharyngeal cancer. After evaluation by the radiation oncologist, radiotherapy at 30 sessions \u002F60Gy is planned.\n4. The expected survival period is more than 6 months.\n5. No radiotherapy for the head and neck has been performed in the past, and no other medications that affect the results of this trial have been used. No chemotherapy or immunotherapy was performed within one month before the beginning of the trial.\n\nExclusion criteria:\n\n1. Uncontrollable local or systemic infections of the oral cavity and head and neck.\n2. Active or history of autoimmune diseases; Diseases requiring systemic steroid hormones or immunosuppressive medications.\n3. Bleeding occurred within 3 months before enrollment, including but not limited to: gastrointestinal bleeding caused by gastric fundus or esophageal varices, increased risk of bleeding caused by portal hypertension, active gastrointestinal bleeding, etc. Or there is a risk of major bleeding as assessed by the researcher.\n4. Arterial\u002Fvenous thrombosis that occurred within 6 months prior to the screening, such as cerebrovascular accidents, deep vein thrombosis and pulmonary embolism, etc.\n5. Interstitial pneumonia or active pneumonia with clinical significance, or other respiratory diseases that seriously affect lung function.\n6. History of cardiovascular diseases, including but not limited to: (1) Congestive heart failure (NYHA grade \\> 2); (2) Unstable angina pectoris; (3) Myocardial infarction occurred in the past three months; (4) Any supraventricular arrhythmia or ventricular arrhythmia that requires treatment or intervention.\n7. Severe endocrine or hematopoietic system diseases (such as diabetes, leukemia, etc.), gastrointestinal obstruction, active bleeding, gastric perforation and other conditions.\n8. Combined with malignant tumors of other organs.\n9. Intractable or refractory epilepsy, with a large amount of pleural effusion, ascites, pericardial effusion, etc. that cannot be controlled by medicines.\n10. History of HIV, syphilis, active hepatitis, active pulmonary tuberculosis, active EBV and\u002For CMV infection within one year before screening, or those with a history of active pulmonary tuberculosis infection for more than one year without regular treatment; active hepatitis B or C. Patients with positive HBsAg or HBcAb can participate in this study if the HBV DNA test is below the lower limit of the normal value detected by the research center; patients with positive HCV antibody can participate in this study if the HCV RNA test is below the lower limit of the normal value detected by the research center.\n11. History of allogeneic bone marrow transplantation or solid organ transplantation.\n12. Have received cell therapy products that have undergone genetic modification or editing in the past.\n13. Have previously used medicines that can cause medication-related osteonecrosis of the jaw.\n14. Have taken drugs containing taurine within one month before randomization in this study.\n15. Allergic to taurine.\n16. Patients who, in addition to radiotherapy, requires chemotherapy or immunotherapy simultaneously.\n17. Mental illness, alcohol abuser, drug user or drug abuser.\n18. Pregnant or lactating women; Women who plans to become pregnant within half a year after treatment.\n19. Poor compliance or other circumstances assessed by the researcher as unsuitable for participation in this clinical study.","ALL","80 Years",{"count":57,"type":20},160,[59],"PHASE2","This is a single-center, double-blind, randomized controlled study. The patients were divided into control group and experimental group, 80 cases each. From the first day of radiotherapy to the end of radiotherapy, the experimental group was treated with 24 grams of taurine granule (containing 4.8 grams of taurine) before each day's radiotherapy. The control group was treated with the same amount of placebo.",[62,27],"Radiation Induced Oral Mucositis",[64,65,66,67,68],"double-blind","randomized controlled trial","taurine","radiodermatitis","radiation-induced oral mucositis","RECRUITING","2026-03-16",{"date":72,"type":39},"2026-03-18",{"date":74,"type":39},"2025-11-24",{"date":76,"type":20},"2027-12-31",{"name":78,"class":46},"Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University",1]